PPA
CYTK icon

Parametric Portfolio Associates’s Cytokinetics CYTK Stock Holding History

Parametric Portfolio Associates’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$9.25M Sell
251,287
-17,299
-6% -$615K ﹤0.01% 1410
2021
Q4 		$12.2M Buy
268,586
+11,896
+5% +$459K 0.01% 1255
2021
Q3 		$9.17M Buy
256,690
+84,307
+49% +$2.48M 0.01% 1419
2021
Q2 		$3.41M Buy
172,383
+5,778
+3% +$136K ﹤0.01% 2120
2021
Q1 		$3.88M Buy
166,605
+10,396
+7% +$222K ﹤0.01% 2339
2020
Q4 		$3.25M Buy
156,209
+1,893
+1% +$34.6K ﹤0.01% 2361
2020
Q3 		$3.34M Sell
154,316
-33,645
-18% -$787K ﹤0.01% 2165
2020
Q2 		$4.43M Buy
187,961
+65,348
+53% +$1.23M ﹤0.01% 1956
2020
Q1 		$1.45M Buy
122,613
+21,680
+21% +$277K ﹤0.01% 2578
2019
Q4 		$1.07M Sell
100,933
-15,420
-13% -$158K ﹤0.01% 3029
2019
Q3 		$1.32M Buy
116,353
+11,783
+11% +$148K ﹤0.01% 2878
2019
Q2 		$1.18M Buy
104,570
+25,783
+33% +$249K ﹤0.01% 2970
2019
Q1 		$637K Sell
78,787
-3,267
-4% -$24K ﹤0.01% 3228
2018
Q4 		$519K Buy
82,054
+21,024
+34% +$154K ﹤0.01% 3294
2018
Q3 		$601K Buy
61,030
+26,651
+78% +$214K ﹤0.01% 3345
2018
Q2 		$285K Sell
34,379
-11,089
-24% -$92.3K ﹤0.01% 3571
2018
Q1 		$327K Buy
45,468
+20,263
+80% +$174K ﹤0.01% 3540
2017
Q4 		$205K Sell
25,205
-11,882
-32% -$135K ﹤0.01% 3746
2017
Q3 		$538K Buy
37,087
+14,072
+61% +$192K ﹤0.01% 3381
2017
Q2 		$278K Buy
23,015
+9,682
+73% +$135K ﹤0.01% 3667
2017
Q1 		$171K Buy
13,333
+189
+1% +$2.21K ﹤0.01% 3628
2016
Q4 		$160K Sell
13,144
-56
-0.4% -$594 ﹤0.01% 3639
2016
Q3 		$121K Sell
13,200
-996
-7% -$10.4K ﹤0.01% 3652
2016
Q2 		$135K Sell
14,196
-54,925
-79% -$451K ﹤0.01% 3688
2016
Q1 		$487K Buy
69,121
+43,405
+169% +$317K ﹤0.01% 3346
2015
Q4 		$269K Buy
25,716
+7,594
+42% +$74.5K ﹤0.01% 3604
2015
Q3 		$121K Buy
18,122
+804
+5% +$5.49K ﹤0.01% 3169
2015
Q2 		$116K Sell
17,318
-34
-0.2% -$223 ﹤0.01% 3858
2015
Q1 		$118K Buy
17,352
+2,622
+18% +$19.6K ﹤0.01% 3839
2014
Q4 		$118K Buy
+14,730
New +$63.2K ﹤0.01% 3887

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Parametric Portfolio Associates's CYTK Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Cytokinetics (CYTK) stake by 6.4% in Q1 2022, selling an estimated $615K and leaving 251,287 shares worth $9.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1410.

Parametric Portfolio Associates first reported a position in CYTK in Q4 2014 and has held it in 30 quarters since. The position peaked at $12.2M in Q4 2021. 240 funds tracked by Wall St. Rank hold CYTK as of Q1 2022.

  • Parametric Portfolio Associates held 251,287 shares of Cytokinetics worth $9.25M as of Q1 2022.
  • Parametric Portfolio Associates sold 17,299 Cytokinetics shares in Q1 2022, an estimated $615K.
  • Cytokinetics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1410 holding.
  • Parametric Portfolio Associates first reported a position in Cytokinetics in Q4 2014 and has held it in 30 quarters since.
  • Parametric Portfolio Associates's Cytokinetics position peaked at $12.2M in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.